Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141492 | 1.00 | KDM4E (0.48) | KDM4EKMT2AGAAALDH1A1HPGD | |
| SCHEMBL141941 | 0.83 | PDE4B (0.45) | KDM4EALDH1A1SMN1; SMN2LMNAPDE4B | |
| SCHEMBL29440158 | 0.83 | PDE4B (0.45) | KDM4EALDH1A1SMN1; SMN2LMNAPDE4B | |
| SCHEMBL142116 | 0.82 | KDM4E (0.59) | KDM4EKMT2AGAAALDH1A1HPGD | |
| SCHEMBL112198 | 0.82 | KDM4E (0.50) | KDM4EKMT2AGAAALDH1A1HPGD | |
| SCHEMBL7353686 | 0.78 | PDE4B (0.61) | KDM4EKMT2AGAAALDH1A1HPGD | |
| SCHEMBL7353680 | 0.78 | PDE4B (0.61) | KDM4EKMT2AGAAALDH1A1HPGD | |
| SCHEMBL17936307 | 0.77 | MAPT (0.42) | KDM4EKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL145748 | 0.76 | KCNA3 (0.42) | KDM4EKMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL145747 | 0.76 | KCNA3 (0.42) | KDM4EKMT2AALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162928-B | Halogenated analogs of anti-fibrotic agents | 塞尔塔医疗有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
| EP-2220028-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079692-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | KDM4E 1397/4885KMT2A 3218/4885GAA 2613/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | KDM4E 1397/4885KMT2A 3218/4885GAA 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.